Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery Jun 29 | 2023NICE Requests Additional Tirzepatide T2DM Data; Insulet Initiates Omnipod 5 + Libre 2 Study; Esperion Files CLEAR Outcomes in EU; Nemaura Expands proBEAT Pilot; NeuroBo and Terns Announce Preclinical Obesity DataPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery Jun 27 | 2023Lilly Poised to Own the Obesity Market; ADA 2023 Key Press Releases (June 26)Purchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Jun 26 | 2023STEP HFpEF Topline Results; Novo ADA 2023 Investor EventPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Jun 26 | 2023FENIX Analysis: Breaking Through Novo and Lilly's Obesity DuopolyPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Jun 26 | 2023Medtronic Admits It Can’t Achieve iCGM Designation?; 2023 ADA Investor EventPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jun 25 | 2023ADA 2023 Key Press Releases (June 24)Purchase Blast
$599
Posted in: Glucose Monitoring Jun 24 | 2023Dexcom to Ride the Obesity Wave; Dexcom 2023 Investor DayPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, SGLT2i Jun 23 | 2023EMA Raises Thyroid Safety Concern Over GLP-1RAs; Madrigal Presents New MAESTRO-NASH Data; Expanded Libre 2 Coverage in France; Bayer Initiates Finerenone CKD + T1DM study; Bigfoot RWE Data Published; Mannkind Initiates INHALE-3 Switching StudyPurchase Blast
$599
Posted in: Other Jun 22 | 2023Intercept to Discontinue OCA NASH Development Following Second CRLPurchase Blast
$599
Posted in: DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, SGLT2i Jun 22 | 2023Novo Files Lawsuit Over Third-Party Semaglutide Promotion; Versanis Bio Completes Enrollment of Ph2b Bimagrumab Study in Obesity; FDA Approves Jardiance and Synjardy for Pediatric T2DM and Lodoco for ASCVDPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, SGLT2i Jun 20 | 2023June CHMP Agenda; AstraZeneca Discontinues Oral GLP-1RA Development; Lilly Launches Insulin Affordability Awareness CampaignPurchase Blast
$599
Posted in: GLP-1RA, Glucagon, Other Jun 16 | 2023Lilly Partners with Verve Therapeutics for Lp(a) Gene Editing Program; Zucara Receives Funding from JDRFPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jun 15 | 2023Wegovy Advertising Paused Due to High Demand; Inventiva Ph2 Lanifibranor T2DM and NAFLD Results; FDA Accepts Gan & Lee’s Bs-Aspart BLAPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, Other Jun 12 | 2023Novartis to Acquire Chinook; Novo Nordisk Expands Danish FacilityPurchase Blast
$599
Posted in: Insulin Delivery, Other Jun 09 | 2023AstraZeneca Partners for T1DM Cell Therapy; New Lilly Care TrialPurchase Blast
$599
Posted in: Glucose Monitoring Jun 08 | 2023Know Labs Unveils Non-Invasive Glucose Monitor PrototypePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Jun 05 | 2023Novo to Acquire Biocorp; Akero Announces Ph2b SYMMETRY Results; Enterin Initiates Ph1a ENT-03 StudyPurchase Blast
$599
Posted in: Dual/triple agonist, Glucose Monitoring, Other Jun 02 | 2023Lilly Initiates Ph3 Retatrutide Obesity Program; UnitedHealthcare Expands Coverage to Eversense E3 CGMPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
